Trefoil Therapeutics
San Diego, US · Founded 2016 · Delaware corporation · 9 known investors
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases. Its lead investigational candidate, TTHX1114, is being studied in a Phase 2 trial for improving visual recovery after Descemet Stripping Only (DSO) procedures.
BiotechHealthtechMedical Devices
Founders & leadership
Trefoil Therapeutics was founded in 2016 by David Eveleth.
DE
David EvelethFounder
SN
Schalon NewtonExecutive
Board
CS
Christy ShafferinBoard director
RB
Ralph BradshawBoard director
Investors · 9
ExSight Ventures✓ verifiedNew York
Solasta Ventures✓ verifiedBoston
Access Biotechnology✓ verifiedNew York City
Bios Partners✓ verifiedFort Worthvia Stella Robertson · board
Correlation Ventures✓ verifiedSan Francisco · $100K – $4M
FemHealth Ventures✓ verifiedShort Hills
Hatteras Venture Partners✓ verifiedResearch Triangle · $500K – $4M
InFocus Capital Partners, LLC✓ verifiedJericho
Bios ClinicalreportedFort Worth
Reported raises · per SEC filings
Form D private placements$33.3M disclosed across 4 rounds · 2016–2025
▶$4.6MraisedMay 2025 · 16 investors · BiotechnologyRule 506(b)
▶$4.6MraisedMay 2025 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christy ShafferDirector
- Stella RobertsonDirector
- Jonathan MowExecutive Officer
- Ben McGrawDirector
- John FucciDirector
- Kseniya SimpsonDirector
- Offering amount
- $5M
- Amount sold
- $4.6M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedMar 2022 · 14 investors · BiotechnologyRule 506(b)
▶$12MraisedMar 2022 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christy ShafferDirector
- Derek YoonDirector
- Stella RobertsonDirector
- Ben McGrawDirector
- David EvelethExecutive Officer, Director
- Schalon NewtonExecutive Officer
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.6MraisedAug 2019 · 13 investors · BiotechnologyRule 506(b)
▶$12.6MraisedAug 2019 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christy ShafferDirector
- Derek YoonDirector
- Stella RobertsonDirector
- Schalon NewtonExecutive Officer
- David EvelethExecutive Officer, Director
- Ben McGrawDirector
- Offering amount
- $28M
- Amount sold
- $12.6M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$4.2MraisedDec 2016 · 14 investors · BiotechnologyRule 506(b)
▶$4.2MraisedDec 2016 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ralph BradshawDirector
- Christy ShafferDirector
- Schalon NewtonExecutive Officer
- David EvelethExecutive Officer, Director
- Offering amount
- $5.2M
- Amount sold
- $4.2M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapHealio13 shared keywordsHealio provides medical news, clinical data, and continuing medical education (CME) for healthcare professionals across specialties such as infectious disease and hepatology. It covers topics including biliary diseases, Ebola, and emerging outbreaks.
Medscape11 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Companies competing with Trefoil Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Trefoil Therapeutics do?
- Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases. Its lead investigational candidate, TTHX1114, is being studied in a Phase 2 trial for improving visual recovery after Descemet Stripping Only (DSO) procedures.
- Who founded Trefoil Therapeutics?
- Trefoil Therapeutics was founded by David Eveleth in 2016.
- Who are Trefoil Therapeutics's investors?
- Trefoil Therapeutics's investors include ExSight Ventures, Solasta Ventures, Access Biotechnology, Bios Partners, Correlation Ventures, FemHealth Ventures, Hatteras Venture Partners, InFocus Capital Partners, LLC and 1 more.
- How much funding has Trefoil Therapeutics raised?
- Trefoil Therapeutics has disclosed $33.3M raised across 4 rounds.
- Where is Trefoil Therapeutics headquartered?
- Trefoil Therapeutics is headquartered in San Diego, US.